[Orphan drugs and orphan diseases]

Area of Science:

• Medical Science
• Genetics
• Pharmacology

Context:

• Rare diseases, defined as affecting 650-1,000 persons per million, encompass approximately 5,000 identified conditions.
• 80% of rare diseases are genetic, with 50% manifesting in childhood, frequently impacting neuropaediatrics and the nervous system.
• Delayed diagnosis in 45% of rare diseases highlights challenges in patient identification and timely intervention.

Purpose:

• To define orphan drugs and diseases, review clinical investigation status, and analyze pharmaceutical industry attitudes and health legislation.
• To explore the historical development and current landscape of orphan drug regulation and utilization.
• To underscore the need for continued efforts in treating rare diseases.

Summary:

• Orphan drugs are vital for treating rare diseases, with over 150 currently available for more than seven million patients.
• The pharmaceutical industry's reluctance to develop treatments for rare diseases due to cost has been addressed by legislative actions, including the US Orphan Drug Act of 1983 and EU regulations since 2000.
• Early diagnosis by specialists is crucial for rare diseases, yet late diagnosis remains a significant issue.

Impact:

• Legislative frameworks like the Orphan Drug Act and EU regulations have spurred the development and availability of orphan drugs.
• Increased availability of orphan drugs has improved access to medical advancements for millions of patients with rare conditions.
• Continued advocacy and research are essential to further advance the treatment and management of rare diseases.